What is Radialogica?
Radialogica operates at the intersection of health technology and oncology, focusing on enhancing the precision and efficacy of radiation therapy. The company provides sophisticated software and quality management solutions designed to improve patient outcomes and mitigate the long-term effects of cancer survivorship. Its services are crucial for clinical practice and clinical trials, fostering collaboration with pharmaceutical companies, biotech firms, and medical device manufacturers to implement robust radiation therapy quality assurance programs. With a global footprint, Radialogica's impact is evident in over 1.5 million patient treatments across more than 225 clinical sites worldwide, positioning it as a leader in its specialized field.
How much funding has Radialogica raised?
Radialogica has raised a total of $4.7M across 4 funding rounds:
Private Equity
$1.3M
Private Equity
$2.9M
Debt
$150K
Debt
$343K
Private Equity (2013): $1.3M, investors not publicly disclosed
Private Equity (2016): $2.9M, investors not publicly disclosed
Debt (2020): $150K supported by PPP
Debt (2021): $343K featuring PPP
Key Investors in Radialogica
PPP
Public-Private Partnership
What's next for Radialogica?
The recent major strategic investment of $343K positions Radialogica for significant expansion and innovation in the competitive healthtech landscape. As an enterprise-level company, this capital infusion is expected to fuel further development of its advanced radiation oncology tools and quality management systems. Strategic deployment of these funds will likely focus on enhancing global reach, deepening partnerships with key industry players, and accelerating the adoption of its solutions in both clinical settings and research trials. Radialogica's trajectory suggests a continued commitment to improving cancer care through technological advancement and data-driven insights.
See full Radialogica company page
